Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.63 |
| ▸ | CSF1R | P07333 | 1/20 | 0.62 |
| ▸ | RET | P07949 | 2/20 | 0.57 |
| ▸ | ACHE | P22303 | 3/20 | 0.55 |
| ▸ | BACE1 | P56817 | 3/20 | 0.55 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | KIF5B | P33176 | 1/20 | 0.53 |
| ▸ | KIT | P10721 | 3/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.47 |
| ▸ | TUBB | P07437 | 1/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.47 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5461541 | 0.97 | EGFR (0.64) | EGFRCSF1RRETACHEBACE1 | |
| SCHEMBL9056703 | 0.92 | EGFR (0.73) | EGFRCSF1RRETACHEBACE1 | |
| Hydrochloric Acid SCHEMBL8652234 | 0.91 | EGFR (0.74) | EGFRCSF1RRETACHEBACE1 | |
| SCHEMBL4717907 | 0.86 | EGFR (0.85) | EGFRCSF1RRETACHEBACE1 | |
| SCHEMBL9112738 | 0.85 | EGFR (0.83) | EGFRCSF1RRETACHEBACE1 | |
| SCHEMBL4719788 | 0.82 | EGFR (0.87) | EGFRCSF1RRETACHEBACE1 | |
| Hydrochloric Acid SCHEMBL6180077 | 0.81 | EGFR (0.87) | EGFRCSF1RRETACHEBACE1 | |
| SCHEMBL4719670 | 0.81 | EGFR (0.61) | EGFRCSF1RRETACHEBACE1 | |
| SCHEMBL8645745 | 0.81 | EGFR (0.69) | EGFRCSF1RRETACHEBACE1 | |
| SCHEMBL9052748 | 0.80 | EGFR (0.75) | EGFRCSF1RRETACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-04-26 | — | — | US | claimed |
| EP-1940819-A1 | PHOSPHODIESTERASE 10 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2008-07-09 | — | — | EP | disclosed |
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-04-26 | — | — | US | disclosed |
| WO-2007022280-A1 | PHOSPHODIESTERASE 10 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
| US-5736534-A | HYPERPROLIFERATIVE DISEASES; INHIBITORS OF PROTEIN-TYROSINE KINASES SUCH AS EPIDERMAL GROWTH FACTOR RECEPTOR; BRAIN, LUNG, BREAST CANCER; PSORIASIS AND BENIGN PROSTATE HYPERPLASIA | PFIZER INC. (US) | 1998-04-07 | — | — | US | disclosed |
| WO-1995023141-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1995-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE12, PDE10A | EGFR 4754/4885CSF1R 4142/4885RET 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.